Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical implications of DNA repair genetic alterations in cancer

Clinical implications of DNA repair genetic alterations in cancer The overall prognosis of advanced cancer remains poor. Whilst accumulation of genetic mutations drives the cancerous phenotype, it is well known that DNA damaging lesions that lead to such mutations are predominantly monitored and repaired by the highly conserved DNA repair machinery in cells. Though chemotherapy as well as radiotherapy remains the mainstay of treatment, it is clear that the cancer cell's ability to respond to DNA damaging lesions induced by cytotoxic agents has a major bearing upon therapeutic efficacy and normal tissue toxicity. In this article we provide an overview on the role of DNA repair factors as prognostic/predictive markers with a specific focus on genetic alterations that confer altered DNA repair capacity in cells. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

Clinical implications of DNA repair genetic alterations in cancer

Download PDF
5 pages

Loading next page...
 
/lp/springer-journals/clinical-implications-of-dna-repair-genetic-alterations-in-cancer-66yrYwP53J
Publisher
Springer Journals
Copyright
Copyright © 2009 by Springer-Verlag
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-009-0093-y
Publisher site
See Article on Publisher Site

Abstract

The overall prognosis of advanced cancer remains poor. Whilst accumulation of genetic mutations drives the cancerous phenotype, it is well known that DNA damaging lesions that lead to such mutations are predominantly monitored and repaired by the highly conserved DNA repair machinery in cells. Though chemotherapy as well as radiotherapy remains the mainstay of treatment, it is clear that the cancer cell's ability to respond to DNA damaging lesions induced by cytotoxic agents has a major bearing upon therapeutic efficacy and normal tissue toxicity. In this article we provide an overview on the role of DNA repair factors as prognostic/predictive markers with a specific focus on genetic alterations that confer altered DNA repair capacity in cells.

Journal

memo - Magazine of European Medical Oncology – Springer Journals

Published: Jan 1, 2009

References

  • Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints
    Sancar, A; Lindsey-Boltz, LA; Unsal-Kacmaz, K
  • Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy
    Gossage, L; Madhusudan, S
  • Eukaryotic nucleotide excision repair: from understanding mechanisms to influencing biology
    Shuck, SC; Short, EA; Turchi, JJ
  • O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy
    Verbeek, B; Southgate, TD; Gilham, DE
  • Genome maintenance mechanisms for preventing cancer
    Hoeijmakers, JH
  • Human syndromes with genomic instability and multiprotein machines that repair DNA double-strand breaks
    De la Torre, C; Pincheira, J; Lopez-Saez, JF
  • The essence of SNPs
    Brookes, AJ
  • Demethylation of (Cytosine-5-C-methyl) DNA and regulation of transcription in the epigenetic pathways of cancer development
    Patra, SK; Patra, A; Rizzi, F
  • Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans
    Shen, MR; Jones, IM; Mohrenweiser, H
  • DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy
    Olaussen, KA; Dunant, A; Fouret, P
  • Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer
    Cobo, M; Isla, D; Massuti, B
  • Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene
    Yu, JJ; Lee, KB; Mu, C
  • Current status of excision repair cross complementing-group 1 (ERCC1) in cancer
    Gossage, L; Madhusudan, S
  • ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review
    Benhamou, S; Sarasin, A
  • Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors
    Bobola, MS; Finn, LS; Ellenbogen, RG
  • Apurinic endonuclease activity in adult gliomas and time to tumor progression after alkylating agent-based chemotherapy and after radiotherapy
    Bobola, MS; Emond, MJ; Blank, A
  • Effects of base excision repair gene polymorphisms on pancreatic cancer survival
    Li, D; Li, Y; Jiao, L
  • Brain tumors: molecular biology and targeted therapies
    Hegi, ME; Murat, A; Lambiv, WL
  • Clinical and molecular consequences of microsatellite instability in human cancers
    Hamelin, R; Chalastanis, A; Colas, C
  • Mismatch repair status is a predictive factor of tumour response to 5-fluorouracil and irinotecan chemotherapy in patients with advanced colorectal cancer
    Bendardaf, R; Lamlum, H; Ristamaki, R
  • Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
    Jover, R; Zapater, P; Castells, A
  • DNA mismatch repair deficiency, resistance to cancer chemotherapy and the development of hypersensitive agents
    Pors, K; Patterson, LH
  • Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma
    Maxwell, JA; Johnson, SP; McLendon, RE
  • In search of the tumour-suppressor functions of BRCA1 and BRCA2
    Scully, R; Livingston, DM
  • BRCA1, a potential predictive biomarker in the treatment of breast cancer
    James, CR; Quinn, JE; Mullan, PB
  • Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers
    Byrski, T; Gronwald, J; Huzarski, T
  • Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations
    Wysocki, PJ; Korski, K; Lamperska, K
  • Determinants and predictive factors of tumour radiosensitivity
    Hennequin, C; Quero, L; Favaudon, V
  • Genetic biomarkers of therapeutic radiation sensitivity
    Fernet, M; Hall, J
  • Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients
    Chistiakov, DA; Voronova, NV; Chistiakov, PA
  • Genetic predictors of adverse radiotherapy effects: the Gene-PARE project
    Ho, AY; Atencio, DP; Peters, S
  • DNA repair pathways as targets for cancer therapy
    Helleday, T; Petermann, E; Lundin, C
  • DNA repair inhibition: a selective tumour targeting strategy
    Madhusudan, S; Hickson, ID
  • PARP inhibitors and cancer therapy – early results and potential applications
    Jones, C; Plummer, ER
  • Targeted therapy for cancer using PARP inhibitors
    Lord, CJ; Ashworth, A